Y-mAbs Therapeutics (YMAB) intends to raise gross proceeds of $92 million from a U.S. IPO, according to an S-1 registration statement.The firm is a late-stage clinical biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback